امسال در هفتمين کنگره بين المللي هپاتيت تهران، آقاي دکتر سيدمحمد ميري (عضو هيات علمي) و آقاي دکتر وفايي منش (فلوي گوارش و کبد) به ارايه دو سخنراني با عناوين ذيل پرداختند.
لينک کتابچه خلاصه مقالات: http://hepatmon.com/en/issue/1957.html

مقاله اول:

O179 THE ROLE OF POLYMORPHISMS NEAR IFNL3 GENE AS PREDICTORS OF RESIDUAL HCV RNA IN BUFFY COAT AFTER SUCCESSFUL ANTIVIRAL THERAPY

Seyyed Mohammad Miri1,2, Heidar Sharafi1,3, Ali Pouryasin4,5, Bita Behnava1,3, Maryam Keshvari5, Pegah Karimi Elizee2, Seyed Moayed Alavian1,3

1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah Medical University, Tehran, IR Iran; 2 Kowsar Medical Institute, Heerlen, The Netherlands; 3 Middle East Liver Diseases (MELD) Center, Tehran, IR Iran; 4 Armin Pathobiology Laboratory, Tehran, IR Iran; 5 Department of Biology, Arsanjan Branch, Islamic Azad University, Arsanjan, IR Iran; 6 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran

Presenting Author: Seyyed Mohammad Miri, Email: drmiri@ gmail.com

Abstract

Background and Aims: The presence of hepatitis C virus (HCV) in cells of extrahepatic organs like peripheral blood mononuclear cells (PBMCs) have important implications for transmission, disease progression, and effective treatment of HCV-infected patients. The impact of host genetics such as polymorphisms near Interferon lambda 3 (IFNL3) on clearance of HCV RNA from buffy coat (BC) following successful clearance of HCV from plasma using Pegylated-IFN (PegIFN) and Ribavirin (RBV) treatment was evaluated in our study. Methods: For detection of residual HCV RNA in BC samples, blood samples of 69 patients with sustained virologic response (SVR) after treatment with PegIFN and RBV were evaluated. Polymorphisms near IFNL3 gene including rs12979860 and rs8099917 were assessed using PCR-RFLP method. Results: The most prevalent rs12979860 and rs8099917 genotypes were CT (49.3%) and TT (62.3%), respectively. Nine (13.04%, 95%CI: 7.01%-22.96%) patients had HCV RNA in their BC samples. The favorable genotypes of the two polymorphisms (rs12979860 CC and rs8099917 TT) were more frequently observed in patients with undetectable HCV RNA in their BC samples than those with HCV RNA in their BC samples (rs12979860 CC, 45% vs. 22.2%, P=0.016 and rs8099917 TT, 66.7% vs. 33.3%, P=0.01). Conclusion: The polymorphisms of IFNL3 could play a crucial role not only in spontaneous clearance of HCV and SVR rate after PegIFN and RBV therapy, but also in the clearance of HCV from BC after PegIFN and RBV therapy.

 

---

مقاله دوم

O182 EFFECTIVENESS OF SOBIOVIR® (SOFOSBUVIR) AND DAKLIBIOX® (DACLATASVIR) FOR TREATMENT OF HEPATITIS C IN PATIENT WITH TALASSEMIA

Farhad Zamani1 , Hossein Ajdarkosh1 , MR Khonsari1 , Amirhossein Faraji1 , Jamshid Vafaeimanesh1,2
 
1 Gastroenterology and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran; 2 gastroentrology &hepatology resarch center.qom university of medical seinces,Qom,Iran
Presenting Author: Jamshid Vafaeimanesh, Email: jvafaeemanesh@yahoo.com
 
Abstract
 
Introduction: Thalassemias are the commonest monogenic disorders in the world and the incidence rate is higher in the Middle East. Regarding to high consanguinity among population, it is estimated that there are 25,000 patients in Iran. Patients with α-thalassemia major are at risk of developing post transfusion hepatitis (PTH). In Iran Among thalassemia caseswere found about (19.3%) patients were HCVAb positive. According to this high prevalence, appropriate treatment of these patients is very important.New Direct Antiviral Agents (DAAs) emerged in 2011. Along with production of new drugs, in 2013, it has aimed to eradicate HCV infection by the end of three following decades. Unfortunately there is not a considerable study about effectiveness of DAAs in treating HCV infection in thalassemia patents, hence we decided to design this study. Method:In this study , fifty thalassemia major patients with chronic HCV infection who have been treated with interferon based regimens and had not shown appropriate response were treated with daklibiox and sobiovir. Noncirrhotic patients treated for 3 months and cirrhotic patients treated for six months. SVR 12 was considered as the response criteria. Result:Patients were 18 to 40 years old with mean age of 30.21±5.9 ,.Fifty six percent were male,88 percent were treated one time,8 percent two times and 4 percent three times. As a virology view, 48 percent of viruses had genotype 1a, 28 percent 3a, 12 percent 1b, 4 percent 2a and 4 percent 3a and 1a..According to fibroscan report 48 percent of patients were cirrhotic and 52 percent were noncirrhotic.After treatment only one patient who had genotype b1 virus did not respond to treatment.Liver enzymes significantly decreased in all patients. AST was IU/dl 89.43 ± 13.64 before treatment , decreased to IU/dl 9.19± 72.37,ALT decreased from 10.56 ± 37.73IU/dl to IU/dl 35.28 ±57.27 (p<0/05). No complications were reported during treatment and after 24 weeks follow up. Conclusion: Sofosbuvir (sobiovir®)-Daclatasvir (daklibiox ®) is an effective treatment with minimal complications in thalassemia patients who have chronic HCV infection.